Utility of Medihope as an addon therapy for Covid 19 patients

Utility of Medihope as an addon therapy for Covid 19 patients: AnOpen labeled, Non-Randomized, Multicentric, Phase III Clinical. - NA

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/027975

Enrollment

880

Registered

2020-09-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J99- Respiratory disorders in diseasesclassified elsewhere Health Condition 2: J99- Respiratory disorders in diseasesclassified elsewhere

Interventions

Intervention1: Medihope: Medihope is a patented Ayurvedic product whose individual components have been mentioned in Ayurvedic texts. None of the individual components belongs to the Schedule E (1) of

Eligibility

Inclusion criteria

Inclusion criteria: 1. Covid-19 patients diagnosed by RTPCR/ Rapid test, willing to participate and comply with all study procedures of the study. 2. Patients with or without history of Diabetes and/or Hypertension. 3. Patients willing to give written informed consent. 4. Patients of age more than 18 years of either gender. 5. Patients with mild (do not require oxygen, SpO2 100%) to moderate (require oxygen but do not require ventilatory support) symptoms of Covid-19 infection.

Exclusion criteria

Exclusion criteria: 1. Patients with previous history of severe respiratory illness, viz Pneumonia, COPD. 2. Patients requiring Ventilatory support. 3. Pregnant and lactating women. 4. Patients with any other acute or chronic illness, viz Crohns disease, Congestive cardiac failure, rheumatoid arthritis, AIDS. 5. Patients receiving medication other than that for diabetes, hypertension. 6. Patients receiving any medication of traditional medicine. 7. Patients with history of allergy. 8. Patients with any psychiatric illness or history of drug abuse.

Design outcomes

Primary

Measure	Time frame
Primary:Chest radiograph, HRCT, SpO2 levels, Arterial Blood Gas and Status at discharge Secondary:temperature, respiratory symptoms and change in CBC, D-dimer, S. ferritin, IL-6, Vitamin D3, C-reactive protein, LDH, LFT, RFT & Duration of stay Timepoint: All the variables will be assessed at Day 1(baseline) and at Day 7 for the mild patients and day 15 for the moderate/severe patients	—

Secondary

Measure	Time frame
Secondary:temperature, respiratory symptoms and change in CBC, D-dimer, S. ferritin, IL-6, Vitamin D3, C-reactive protein, LDH, LFT, RFT & Duration of stay Timepoint: Upto 15 days from the date of enrollment	—

Countries

India

Contacts

Public ContactDr Rahul Kunkulol

Rural Medical college Loni

kalpesh.game@gmail.com9975716830

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026